Tango Therapeutics (TNGX) Non-Current Deffered Revenue (2020 - 2025)

Tango Therapeutics' Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $30.4 million for Q2 2025.

• In Q2 2025, Non-Current Deffered Revenue fell 44.09% year-over-year to $30.4 million; the TTM figure through Jun 2025 stood at $30.4 million (down 44.09% YoY), while the FY2024 annual figure was $44.8 million, down 32.87% from the prior year.
• Non-Current Deffered Revenue was $30.4 million for Q2 2025 at Tango Therapeutics, down from $37.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $116.6 million in Q3 2021 to a low of $5.8 million in Q1 2021.
• Historically, Non-Current Deffered Revenue has averaged $68.3 million across 5 years, with a median of $68.7 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Non-Current Deffered Revenue soared 1898.7% in 2021, then tumbled 44.09% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $114.7 million in 2021, then fell by 19.73% to $92.1 million in 2022, then declined by 27.59% to $66.7 million in 2023, then sank by 32.87% to $44.8 million in 2024, then plunged by 32.01% to $30.4 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $30.4 million (Q2 2025), $37.5 million (Q1 2025), and $44.8 million (Q4 2024), per Business Quant data.